The cancer anorexia-cachexia syndrome: myth or reality?

被引:32
|
作者
Lasheen, Wael [2 ]
Walsh, Declan [1 ,2 ]
机构
[1] Cleveland Clin, Cleveland, OH 44195 USA
[2] Taussig Canc Inst, Cleveland Clin, Dept Solid Tumor Oncol, Harry R Horvitz Ctr Palliat Med, Cleveland, OH USA
关键词
Cancer; Cachexia; Anorexia; Anorexia-cachexia; Symptoms; Symptom burden; Survival; Prognosis; Palliative care; MEGESTROL-ACETATE; WEIGHT-LOSS; FOOD-INTAKE; CHEMOTHERAPY; DEFINITION; SYMPTOMS; THERAPY; PLACEBO;
D O I
10.1007/s00520-009-0772-6
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Controversy exists as what constitutes the cancer anorexia-cachexia syndrome (CACS), and whether it truly is a distinct clinical disorder. In this study, we aimed to: (1) assess if CACS is a distinct clinical disorder, (2) identify the symptoms characteristic of CACS, (3) evaluate CACS impact on patient outcomes (symptom burden and survival time from referral). Consecutive patients referred to palliative medicine were assessed by 38-symptom questionnaire. Demographics, Eastern Cooperative Oncology Group (ECOG), disease and extent, and survival were recorded. CACS, defined as anorexia plus weight loss (> 10% of pre-illness weight). For analysis, patients were divided into four groups: (1) group CACS; (2) group A (only anorexia, NO > 10% pre-illness weight loss); (3) group WL (weight loss > 10% pre-illness weight only but NO anorexia); and (4) group N (NO weight loss > 10% pre-illness weight and NO anorexia). Symptoms present in a parts per thousand yen5%, and patients with complete data were analyzed. Four hundred eighty-four patients had complete data, metastatic cancer, and 26 symptoms present in a parts per thousand yen5%. Groups had significantly different ECOG, symptom burden, and survival. Significantly different symptom prevalence between groups: dry mouth,*early satiety,*constipation,*nausea,*taste changes,*vomiting,*dysphagia,*fatigue,*weak,*lack of energy, insomnia, dyspnea, depression, hoarseness, and anxiety. The nine symptoms with asterisk were CACS specific. Symptom Burden: CACS independently predicted greatest burden. Survival: Group N had significantly longer survival. CACS appeared to be a distinct disorder with unique clinical characteristics in our advanced cancer population. Nine other symptoms constituted CACS. CACS independently predicted higher symptom burden. CACS absence predicted longer survival. More evidence is needed to better characterize this syndrome and generate a valid CACS consensus. A comprehensive validated CACS assessment instrument is required.
引用
收藏
页码:265 / 272
页数:8
相关论文
共 50 条
  • [21] Neural control of the anorexia-cachexia syndrome
    Laviano, Alessandro
    Inui, Akio
    Marks, Daniel L.
    Meguid, Michael M.
    Pichard, Claude
    Rossi Fanelli, Filippo
    Seelaender, Marilia
    AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 2008, 295 (05): : E1000 - E1008
  • [22] Cancer anorexia-cachexia syndrome - Psychological effect on the patient and family
    McClement, S
    JOURNAL OF WOUND OSTOMY AND CONTINENCE NURSING, 2005, 32 (04) : 264 - 268
  • [23] Integrative role of neuropeptides and cytokines in cancer anorexia-cachexia syndrome
    Patra, Surajeet K.
    Arora, Sarika
    CLINICA CHIMICA ACTA, 2012, 413 (13-14) : 1025 - 1034
  • [24] Nutrition support and pharmacotherapy in cancer patients with anorexia-cachexia syndrome
    Snegovoy, Anton
    Manzuk, Ludmila
    Kanagavel, Dheepak
    Blokhin, N. N.
    ANNALS OF ONCOLOGY, 2007, 18 : 195 - 195
  • [25] Cancer anorexia-cachexia syndrome: Current issues in research and management
    Inui, A
    CA-A CANCER JOURNAL FOR CLINICIANS, 2002, 52 (02) : 72 - 91
  • [26] SEOM clinical guidelines for cancer anorexia-cachexia syndrome (2023)
    Rivas, Ainara Soria
    Alvarez, Yolanda Escobar
    Cordellat, Ana Blasco
    Tarruella, Margarita Majem
    Mata, Kevin Molina
    Sanchez, M. del Mar Munoz
    de la Camara, Marta Motilla
    Poves, Marta Zafra
    Zambrano, Carmen Beato
    Gutierrez, Luis Cabezon
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2024, 26 (11): : 2866 - 2876
  • [27] Pharmacological therapy of cancer anorexia-cachexia
    Cardona, D.
    NUTRICION HOSPITALARIA, 2006, 21 : 17 - 26
  • [28] BRAIN TRYPTOPHAN AND THE NEOPLASTIC ANOREXIA-CACHEXIA SYNDROME
    KRAUSE, R
    JAMES, JH
    ZIPARO, V
    FISCHER, JE
    CANCER, 1979, 44 (03) : 1003 - 1008
  • [29] Assessing and managing the symptoms associated with the anorexia-cachexia syndrome in cancer patients
    Andrew, I.
    Holden, K.
    Hawkins, C.
    PHARMACY WORLD & SCIENCE, 2008, 30 (04): : 420 - 420
  • [30] New drugs for the anorexia-cachexia syndrome.
    Davis M.P.
    Current Oncology Reports, 2002, 4 (3) : 264 - 274